Login to Your Account

Washington Roundup

Value of Exclusivity Leads to FDA Challenges, Debate

By Mari Serebrov
Washington Editor

Friday, January 25, 2013
With exclusivity assuming a bigger role in the life cycle of a drug, Gilead Sciences Inc. wants more for its Stribild HIV drug than the three-year exclusivity the FDA typically grants to new fixed-dose combination (FDC) drugs.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription